Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupCD20+High riskICD10C82.-C82.7C82.9C83.3C83.7C84.4C84.6C84.7C85.2C86.1C86.2C86.5C94.7-MeSHBurkitt LymphomaLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, DiffuseMediastinal NeoplasmsSequenceBRNT1.8/NIVO240, NHL, C1 (PID1516) -|- C2+ (PID1515)DA-EPOCH (ETOP50/PRED120/VNCR0.4/CYCL750/DOXO10)/RITU375, B-NHL, C1-2 (PID658) -|- C3-6 (PID2056)DA-EPOCH-R(R), Burkitt's lymphomaEPCO(0.16/0.8/48), DLBCL, C1 (PID2486) -|- C2-3 (PID2487) -|- C4-9 (PID2488) -|- C10+ (PID2489)STUDY - levelChemotherapyChemo-substanceBrentuximab vedotinCyclophosphamideDoxorubicinEpcoritamabEtoposideGemcitabineMethotrexateNaCl 0.9%NivolumabOxaliplatinPembrolizumabPrednisoloneRituximabVincristineChemo-substanceBrentuximab vedotinCyclophosphamideDoxorubicinEpcoritamabEtoposideGemcitabineMethotrexateNaCl 0.9%NivolumabOxaliplatinPembrolizumabPrednisoloneRituximabVincristineChemo-substanceBrentuximab vedotinCyclophosphamideDoxorubicinEpcoritamabEtoposideGemcitabineMethotrexateNaCl 0.9%NivolumabOxaliplatinPembrolizumabPrednisoloneRituximabVincristineChemo-substanceBrentuximab vedotinCyclophosphamideDoxorubicinEpcoritamabEtoposideGemcitabineMethotrexateNaCl 0.9%NivolumabOxaliplatinPembrolizumabPrednisoloneRituximabVincristineNo. Substances123478 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDimetindenGranisetronMesnaParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDimetindenGranisetronMesnaParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDimetindenGranisetronMesnaParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDimetindenGranisetronMesnaParacetamolPegfilgrastimPrednisoloneNo. Substances12367910Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityDose intensifiedStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseConsolidationTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlColitisCytokine Release SyndromeDiarrheaEdemaEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaHeadacheHepatotoxicityHyperthyroidismHypothyroidismNeuropathyNeurotoxicityNeutropeniaPneumonitisPyrexiaRashThrombocytopenia below 50 000/µlTumor Lysis Syndrome only studiesPublicationAuthorArmand PDunleavy KHeld GThieblemont CZinzani PDiseaseErstlinientherapie beim primär mediastinalen B-Zell Lymphomprimär mediastinales Non-Hodgkin-Lymphom, R/R, CD30+, ECOG 0-1rezidivierendes (erstlinie mit Anthrazyklin) oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2, ECOG 0-2rezidivierendes oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2Rezidiviertes oder therapierefraktäres primär mediastinales B-Zell-Lymphom, ECOG 0-1Rezidiviertes und therapierefraktäres DLBCL, follikuläres Lymphom °IIIB, mind. 2 Vortherapien, ECOG 0-2OriginCenter for Cancer Research, Divison of Cancer Treatment and Diagnosis, National Cancer Institute, BethesdaDana-Farber Cancer Institute, Boston, USA, KEYNOTE170Hopital Saint-Louis, Hemato-oncologie, Universite de Paris, Paris, FranceInstitute of Hematology Seragnoli, Bologna University, Bologna, Italy, Checkmate 436Internal Medicine I Saarland University Medical School, DSHNHL 2015-1Protocols in Revision 17 protocols foundProtocols under revision.Brentuximab Vedotin 1.8 / Nivolumab 240, Non-Hodgkin Lymphoma, Cycle 1 (PID1516 V1.0)Brentuximab Vedotin 1.8 / Nivolumab 240, Non-Hodgkin Lymphoma, Cycle 2+ (PID1515 V1.0)DA-EPOCH-R - Rituximab 375 / Etoposide 50 / Prednisolone 60 / Vincristine 0.4 / Cyclophosphamide 750 / Doxorubicin 10, B-non-Hodgkin Lymphoma, Cycle 1-2 (PID658 V1.2)DA-EPOCH-R - Rituximab 375 / Etoposide 72 / Prednisolone 60 / Vincristine 0.4 / Cyclophosphamide 1080 / Doxorubicin 14.4, B-Non-Hodgkin Lymphoma, Cycle 3-6 (PID2056 V1.2)Epcoritamab (0.16/0.8/48), diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID2486 V1.1)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, cycle 10+ (PID2489 V1.1)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, Cycle 2-3 (PID2487 V1.1)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, cycle 4-9 (PID2488 V1.1)Pembrolizumab, B-NHL, Primary Mediastinal (PID1545 V1.0)Study - Level - Gemcitabine 1000 / Oxaliplatin 100, Aggressive Non-Hodgkin Lymphoma (PID972 V1.0)Study - Level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID968 V1.2)Study - level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID970 V1.2)Study - Level - Nivolumab 240 / Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID967 V1.2)Study - level - Nivolumab 240 / Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID969 V1.2)Study - Level - Nivolumab 240, diffuse large B-Non-Hodgkin Lymphoma, consolidation (PID971 V1.1)Study - Level - Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID973 V1.0)Study - Level - Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 2+ (PID974 V1.0)
